PerpEquities

Samsung Biologics Co., Ltd. (SSBIOLOGICS) balance sheet

KSC · Healthcare · Biotechnology · 5,455 employees · CEO John Chongbo Rim

Price
$1,001 -0.1%
Market cap
$48.5B
Enterprise value
₩65.5T Data as of 2026-11-21
Last report
Q3 '26 filed 2026-09-30
Next report
2027-01-27 EPS est. ₩11,137.25

At the end of Q3 '26 Samsung Biologics Co., Ltd. (SSBIOLOGICS) held ₩2.32T in cash and short-term investments against ₩1.04T of debt incl. leases. Total assets ₩12.7T, total liabilities ₩3.98T, shareholders' equity ₩8.69T.

Balance sheet

Balance sheetTrendQ4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Assets
Cash & equivalents₩368B₩1.06T₩974B₩540B₩391B₩752B₩709B₩922B₩149B₩520B₩289B₩686B
Short-term investments₩1.69T₩957B₩595B₩448B₩940B₩533B₩935B₩1.01T₩1.31T₩1.1T₩1.9T₩1.64T
Receivables₩743B₩760B₩1.03T₩0₩0₩0₩905B₩1.16T₩780B₩693B₩753B₩792B
Inventory₩2.64T₩2.66T₩2.76T₩2.69T₩2.82T₩2.87T₩3.08T₩3.12T₩2.13T₩2.29T₩2.34T₩2.3T
Other current assets₩4.51B₩49.1B₩7.11B₩1.07T₩1.25T₩980B₩57.2B₩30.9B₩29.1B₩32.6B₩24.4B₩20.7B
Current assets₩5.52T₩5.6T₩5.43T₩4.81T₩5.52T₩5.26T₩5.71T₩6.36T₩4.41T₩4.66T₩5.33T₩5.44T
Property, plant & equipment (net)₩4.34T₩4.79T₩4.82T₩5.15T₩5.84T₩6.26T₩6.22T₩6.19T₩6.04T₩6.75T₩6.75T₩6.63T
Long-term investments-₩1.62T₩305B₩42.8B₩0₩0₩0₩61.1B₩372B₩386B₩355B₩328B₩317B
Goodwill₩1.68T₩1.68T₩1.68T₩1.68T₩1.68T₩1.68T₩1.68T₩1.68T₩0₩0₩0₩0
Intangible assets₩4.15T₩4.11T₩4.06T₩4T₩3.89T₩3.83T₩1.03T₩3.71T₩60.2B₩75.7B₩76.8B₩74.2B
Deferred tax assets₩1.97T₩0₩2.82T₩0₩165M₩165M₩152M₩157M₩133B₩143B₩149B₩176B
Other non-current assets₩2K₩32.4B-₩2.51T₩387B₩415B₩398B₩3.08T₩24.7B₩35.5B₩12.3B₩20.1B₩24.5B
Non-current assets₩10.5T₩10.9T₩10.9T₩11.2T₩11.8T₩12.2T₩12.1T₩12T₩6.65T₩7.33T₩7.32T₩7.23T
Total assets₩16T₩16.5T₩16.3T₩16T₩17.3T₩17.4T₩17.8T₩18.3T₩11.1T₩12T₩12.7T₩12.7T
Liabilities
Accounts payable₩208B₩187B₩169B₩191B₩178B₩184B₩216B₩254B₩59.8B₩214B₩183B₩214B
Accrued expenses₩0₩0₩275B₩0₩0₩0₩689B₩0₩0₩0₩0₩0
Short-term debt₩1.39T₩1.44T₩1.22T₩607B₩327B₩282B₩282B₩326B₩327B₩320B₩407B₩235B
Taxes payable₩191B₩236B₩193B₩281B₩375B₩325B₩0₩317B₩0₩0₩0₩0
Deferred revenue₩2.42T₩1.29T₩1.35T₩0₩0₩0₩0₩1.92T₩1.35T₩166B₩1.57T₩1.49T
Other current liabilities₩864M₩1.5T₩684B₩1.8T₩2.05T₩2.47T₩2.38T₩954B₩439B₩1.5T₩477B₩548B
Current liabilities₩4.16T₩4.65T₩4.03T₩3.56T₩3.85T₩3.62T₩3.64T₩3.77T₩2.53T₩2.74T₩2.97T₩2.7T
Long-term debt₩240B₩195B₩245B₩215B₩1.01T₩1.06T₩1.06T₩893B₩600B₩599B₩599B₩599B
Lease obligations (non-current)₩138B₩72.9B₩71.9B₩9.53B₩7.89B₩6.34B₩4.38B₩2.66B₩1.11B₩249B₩236B₩202B
Deferred revenue (non-current)₩440B₩364B₩406B₩509B₩536B₩477B₩513B₩515B₩453B₩348B₩441B₩428B
Deferred tax liabilities₩1.18T₩1.18T₩1.2T₩1.07T₩972B₩945B₩898B₩908B₩0₩30.8B₩15.3B₩12B
Other non-current liabilities₩55.8B₩53.8B₩59.8B₩65.2B₩49.7B₩51B₩52.8B₩68B₩23.4B₩106B₩34B₩44.2B
Non-current liabilities₩2.06T₩1.87T₩1.98T₩1.87T₩2.58T₩2.54T₩2.53T₩2.39T₩1.08T₩1.33T₩1.32T₩1.29T
Total liabilities₩6.22T₩6.51T₩6.01T₩5.43T₩6.43T₩6.16T₩6.17T₩6.16T₩3.61T₩4.07T₩4.29T₩3.98T
Equity
Common stock & paid-in capital₩178B₩178B₩178B₩178B₩178B₩178B₩178B₩178B₩116B₩116B₩116B₩116B
Retained earnings₩4T₩4.18T₩4.5T₩4.77T₩5.09T₩5.46T₩5.79T₩6.36T₩6.87T₩7.34T₩7.77T₩8.16T
Accumulated other comprehensive income-₩13.8B-₩13.5B-₩13.4B-₩14.6B-₩23B-₩23.1B-₩24.8B-₩22.6B-₩2.93T-₩2.93T-₩2.92T-₩2.98T
Shareholders' equity₩9.83T₩10T₩10.3T₩10.6T₩10.9T₩11.3T₩11.6T₩12.2T₩7.45T₩7.92T₩8.36T₩8.69T
Debt
Total debt (incl. leases)₩1.91T₩1.71T₩1.68T₩970B₩1.49T₩1.42T₩1.42T₩1.22T₩928B₩1.19T₩1.24T₩1.04T
Net debt (debt - cash)₩1.54T₩650B₩708B₩430B₩1.1T₩667B₩708B₩299B₩779B₩674B₩953B₩351B

Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in KRW.

Cash, investments and debt

quarter ends

The other statements

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings.

Data as of 2026-11-21 · Amounts in KRW as reported; price and market cap in USD.